{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=encorafenib+%2B+binimetinib&page=2", "query": { "intervention": "encorafenib + binimetinib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 36, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=encorafenib+%2B+binimetinib&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=encorafenib+%2B+binimetinib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T00:20:10.899Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03973918", "title": "Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Glioma", "BRAF V600E", "BRAF V600K", "Anaplastic Astrocytoma", "Anaplastic Pleomorphic Xanthoastrocytoma", "Gliosarcoma", "Glioblastoma" ], "interventions": [ { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Research Bloods", "type": "BIOLOGICAL" }, { "name": "Tumor Tissue", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-07-29", "completion_date": "2023-10-01", "has_results": true, "last_update_posted_date": "2024-10-31", "last_synced_at": "2026-10-05T00:20:10.899Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Winston-Salem, North Carolina", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03973918" }, { "nct_id": "NCT04044430", "title": "Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Microsatellite Stable Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Stage III Colon Cancer", "Stage III Colorectal Cancer", "Stage III Rectal Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Colorectal Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Colorectal Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Colorectal Cancer", "Stage IIIC Rectal Cancer", "Stage IV Colon Cancer", "Stage IV Colorectal Cancer", "Stage IV Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Colorectal Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Colorectal Cancer", "Stage IVB Rectal Cancer", "Stage IVC Colon Cancer", "Stage IVC Colorectal Cancer", "Stage IVC Rectal Cancer" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-08-31", "completion_date": "2022-07-31", "has_results": false, "last_update_posted_date": "2023-01-09", "last_synced_at": "2026-10-05T00:20:10.899Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04044430" }, { "nct_id": "NCT03911869", "title": "An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Metastases" ], "interventions": [ { "name": "encorafenib", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2019-04-30", "completion_date": "2022-01-27", "has_results": true, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-10-05T00:20:10.899Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Santa Monica, California + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03911869" }, { "nct_id": "NCT01543698", "title": "A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors Harboring a BRAF V600 Mutation" ], "interventions": [ { "name": "LGX818", "type": "DRUG" }, { "name": "MEK162", "type": "DRUG" }, { "name": "LEE011", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 189, "start_date": "2012-05-28", "completion_date": "2023-03-09", "has_results": true, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-10-05T00:20:10.899Z", "location_count": 6, "location_summary": "Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01543698" }, { "nct_id": "NCT01909453", "title": "Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "LGX818", "type": "DRUG" }, { "name": "MEK162", "type": "DRUG" }, { "name": "vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 921, "start_date": "2013-09-12", "completion_date": "2024-09-03", "has_results": true, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-05T00:20:10.899Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01909453" }, { "nct_id": "NCT04903119", "title": "Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "BRAF Gene Mutation" ], "interventions": [ { "name": "Nilotinib 100mg", "type": "DRUG" }, { "name": "Nilotinib 200mg", "type": "DRUG" }, { "name": "Nilotinib 300mg", "type": "DRUG" }, { "name": "Nilotinib 400mg", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rina Plattner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-06-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-05T00:20:10.899Z", "location_count": 4, "location_summary": "Iowa City, Iowa • Lexington, Kentucky • Easton, Pennsylvania + 1 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Easton", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04903119" }, { "nct_id": "NCT04511013", "title": "A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acral Lentiginous Melanoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Cutaneous Melanoma", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Metastatic Mucosal Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2021-01-06", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-05T00:20:10.899Z", "location_count": 331, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 234 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04511013" }, { "nct_id": "NCT02928224", "title": "Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "BRAF V600E-mutant Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Folinic Acid", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 702, "start_date": "2016-10-13", "completion_date": "2022-11-10", "has_results": true, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-10-05T00:20:10.899Z", "location_count": 90, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 45 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02928224" }, { "nct_id": "NCT04800822", "title": "PF-07284892 in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "PF-07284892", "type": "DRUG" }, { "name": "lorlatinib", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "encorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2021-03-17", "completion_date": "2024-06-19", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-05T00:20:10.899Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04800822" }, { "nct_id": "NCT04324112", "title": "Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hairy Cell Leukemia" ], "interventions": [ { "name": "binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2020-10-28", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-05T00:20:10.899Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04324112" } ] }